1. Articles in category: Funding

    1-25 of 25
    1. Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to entrectinib for “treatment of NTRK fusion-positive solid tumors.” NTRK fusions are molecular alterations that occur in a broad variety of adult and pediatric solid tumor types. Entrectinib is the company’s investigational, orally available, CNS-active tyrosine kinase inh

      Read Full Article
      Mentions: Treatment ALK
    2. Orphan designation: Chimeric monoclonal antibody against GD2, for the: Treatment of neuroblastoma

      Review of designation Orphan designation On 8 November 2012, orphan designation (EU/3/12/1062) was granted by the European Commission to Apeiron Biologics AG, Austria, for chimeric monoclonal antibody against GD2 for the treatment of neuroblastoma. This medicine is now known as dinutuximab beta. Chimeric monoclonal antibody against GD2 has been authorised in the EU as Dinutuximab beta Apeiron since 8 May 2017. What is neuroblastoma?

      Read Full Article
      Mentions: Antibody Treatment
    3. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      Drug Deliv Transl Res. 2017 Apr 21;:

      Authors: Gilabert-Oriol R, Chernov L, Anantha M, Dragowska WH, Bally MB

      Abstract Topotecan is a drug that is under investigation for the treatment of neuroblastoma and has been encapsulated into liposomes to improve its therapeutic efficacy.

      Read Full Article
      Mentions: Treatment
    4. Orphan designation: Iodine (131I) murine IgG1 monoclonal antibody against CD276, for the: Treatment of neuroblastoma

      Review of designation Orphan designation On 27 February 2017, orphan designation (EU/3/17/1839) was granted by the European Commission to Y-mAbs Therapeutics A/S, Denmark, for iodine ( 131 I) murine IgG1 monoclonal antibody against CD276 (also known as 131 I-mu8H9) for the treatment of neuroblastoma. What is neuroblastoma? Neuroblastoma is a cancer of certain nerve cells which is usually seen as a lump in the abdomen or around the spine.

      Read Full Article
      Mentions: Antibody Treatment
    5. ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      Scientists from The Institute of Cancer Research, London, have been awarded £1.5 million by the charity Children with Cancer UK to advance precision medicine in the UK and improve cancer treatment for children and young adults.

      Read Full Article
      Mentions: Treatment
    6. Landmark Lions project to provide genome sequencing to hundreds of Aussie kids with cancer

      ( Garvan Institute of Medical Research ) Hundreds of Australian children with high-risk cancer will have access to new genome sequencing technologies that could guide their treatment, following the announcement today of substantial Lions Club funding for the Lions Kids Cancer Genome Project -- an important new component of the Zero Childhood Cancer Program for diagnosis and treatment of childhood cancer.

      Read Full Article
      Mentions: Genetics
    7. Buster Posey to help fight pediatric cancer

      Buster Posey to help fight pediatric cancer

      "It's not acceptable," Posey said as he sat at a table with his wife, Giants president and CEO Larry Baer and New Era president and CEO Chris Koch. "We said we've got to do something. We can't sit here and talk about how bad this, we've got to try to help." At one point Posey choked back tears as he talked about Cannon Wiggins, a 4-year-old who had recently been diagnosed with neuroblastoma.

      Read Full Article
    8. University of Pennsylvania to Join First-of-Its-Kind Research Collaboration to Fight Cancer with New Immunotherapies

      University of Pennsylvania to Join First-of-Its-Kind Research Collaboration to Fight Cancer with New Immunotherapies

      “We are at an inflection point in cancer research and now is the time to maximize immunotherapy’s unique potential to transform all cancers into manageable diseases, saving millions of lives,” said Sean Parker, President of The Parker Foundation. “We believe that the creation of a new funding and research model can overcome many of the obstacles that currently prevent research breakthroughs. Working closely with our scientists and more than 30 industry partners, the Parker Institute is positioned to broadly disseminate discoveries and, most importantly, more rapidly deliver treatments to patients.”

      Read Full Article
      Mentions: Immunotherapy
    9. Childhood Cancer Advocates Take Capitol Hill

      Childhood Cancer Advocates Take Capitol Hill

      "More than 300 cancer advocates from across the US - including more than 35 kids who are survivors - are hitting Capitol Hill on Monday and Tuesday to call on Congress to provide more funding for research and to pass the Childhood Cancer STAR ACT. June 15 and 16 mark the fourth annual Childhood Cancer Action Days coordinated by the Alliance for Childhood Cancer."

      Read Full Article
      Mentions: Treatment
    10. A second chance for children with cancer

      A second chance for children with cancer

      Today most cases of childhood cancer can be cured. However, in about 20 percent of cases children suffer a recurrence of the cancer following therapy and they ultimately succumb to the disease. With a new project called INFORM*, scientists from the German Cancer Research Center (DKFZ) and the German Consortium for Translational Cancer Research (DKTK) aim to provide these children with a second avenue toward cures.

      Read Full Article
      Mentions: GPOH Relapse
    11. Project:EveryChild

      Project:EveryChild

      The Children’s Oncology Group, the world’s largest organization devoted to childhood and adolescent cancer research, will partner with families of children with cancer in to discover the cause of all childhood cancers. In , every type of childhood cancer, no matter how rare, will be studied by the more than 200 pediatric cancer programs of The Children’s Oncology Group, as we lead the way towards better cures.

      Read Full Article
    12. ACT FAST Trial to Open in September

      September marks national Childhood Cancer Awareness month, and the opening of a highly-anticipated SKC-funded clinical trial. The same researchers who made headlines in the New York Times for curing 9-year-old Emily Whitehead of her leukemia using her own immune cells will open a clinical trial at the Children’s Hospital of Philadelphia and at the University of Utah using the same technology to treat children with high-risk neuroblastoma.

      Read Full Article
    13. Charity pledges £500,000 towards Future Fund campaign for specialist childhood cancer centre in Newcastle

      Charity pledges £500,000 towards Future Fund campaign for specialist childhood cancer centre in Newcastle

      Chris Peacock, Chairman of North of England Children's Cancer Research Fund (NECCR) presents a cheque for £500,000 to Newcastle University's 'Future Fund' accepted by Dr. Katie Harland, Senior Development Manager A campaign to establish a £5.5m specialist childhood cancer centre in the region has receeived a £500,000 boost from a local charity.

      Read Full Article
    14. Alexander Strong’s appeal money donated to Ncca Uk

      The family of Alexander ‘Lex’ Strong, who had neuroblastoma, have decided to donate his appeal money to a charity which helps families affected by the same illness.

      £60,000 will be given to the NCCA UK, a charity which supports families facing neuroblastoma, an aggressive childhood cancer.

      Lex was first diagnosed with neuroblastoma on Christmas Eve 2009. Sadly, he lost his battle in January 2013 after fighting the disease for two years from the age of 5.

      Read Full Article
    15. Stand Up To Cancer and St. Baldrick’s Pediatric Cancer Dream Team Announced

      The announcement of the Stand Up to Cancer and St. Baldrick’s pediatric cancer dream team brings great excitement and promise.  The $14.5 million dollar grant was announced yesterday and awarded to Dr. J.M. Maris (CHOP) and Dr. C.L. Mackall (NCI) to pursue their work in the area of “Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”.

      Read Full Article
    16. Paladin Labs in licensing agreement for APN311 (ch14.18)

      Paladin Labs Inc. have entered into an exclusive licensing agreement with Apeiron Biologics AG for APN311, the ch14.18 chimeric monoclonal antibody currently in a SIOPEN Phase III clinical trial across Europe. The license grants Paladin rights to market and sell APN311 in Canada and parts of Africa.

      See the associated press release for further details.

      Read Full Article
      Mentions: Antibody SIOPEN
    17. Neuroblastoma Parent Conference July 29-30

      During the past decade, CNCF has succeeded in bringing an ambitious idea to life. Inviting NB experts to Chicago to speak, providing lodging, meals, some travel funds, and activities for children for NB families who could not otherwise afford to attend such a meeting is a remarkable accomplishment. No other foundation has attempted to duplicate this effort for any other rare disease to our knowledge.

      Read Full Article
    1-25 of 25
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) ALK
  4. General Informations in the News

    1. (1 articles) Treatment